Drug Development Archives - Infectious Diseases Hub

4 June, 2019 0 The ASPECT-NP study, rationale, results and repercussions – an interview with Igancio Martin-Loeches and Marin Kollef

ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.

News

30 May, 2019 0 FDA rejects Nabriva’s antibiotic Contepo for complicated UTIs: May’s industry headlines

Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.

Bacterial

23 May, 2019 0 A peek behind the paper – Nuno Cerca on combating bacterial vaginosis

Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Could targeting neighboring bacterial populations help to combat bacterial vaginosis?’, as we ask the authors about the challenges in treating bacterial vaginosis (BV) and the future of this field.

Bacterial

16 May, 2019 0 Laser-induced vapor nanobubbles: a new local hotspot in the anti-biofilm landscape?

Based on the demonstrated potential of laser-induced vapor nanobubbles to treat bacterial biofilm infections, we provide recommendations for future work in order to further mature this new technology into a promising anti-biofilm approach.

Bacterial

2 May, 2019 0 Gentamicin–azithromycin combination could be effective for drug-resistant gonorrhea

New research has suggested that a combination treatment of gentamicin with azithromycin was almost as effective as the currently used ceftriaxone for treating genital gonorrhea.

News

30 April, 2019 0 Positive opinions from US FDA and EMA for ViiV Healthcare’s Dovato®: April’s industry headlines

Take a look at this month’s industry headlines including news from ViiV Healthcare on long-acting and single dose formulations, sales for Eli Lilly and the possible development of a plague vaccine.

Clinical

15 April, 2019 0 ECCMID19: Suvratoxumab completes Phase II for treatment of Staphylococcus aureus in the New Drugs 4 Bad Bugs program

Collaborative research efforts have seen a novel monoclonal antibody, suvratoxumab, complete a Phase II trial targeted towards Staphylococcus aureus. This SAATELLITE study comes as the first clinical trial in the Innovative Medicines Initiative, formed to develop alternative medicines to combat antibiotic resistance.

HIV / AIDS

10 April, 2019 0 HIV: new imaging reveals targets on the viral envelope

New research describes the use of small-molecule CD4 mimetic compounds that force HIV to undergo conformational changes, exposing normally hidden parts of the envelope and potential new targets.

News

28 March, 2019 0 Phase III study of Novavax’s RSV vaccine fails primary objective: March’s industry headlines

Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.

Malaria

11 March, 2019 0 Experimental antimalarial shows promise in human challenge study

A single, oral dose of antimalarial DSM265 has cleared seven volunteers of a Plasmodium falciparum infection, according to the trial from the Medicines for Malaria Venture.

Microbiome therapeutics – the pipeline for C. difficile infection

Browsing: Basic > Drug Development

Thank you for subscribing, your log-in details have been emailed to you.